Precigen (PGEN) Gets a Buy from JMP Securities

JMP Securities analyst Jason Butler reiterated a Buy rating on Precigen (PGENResearch Report) today and set a price target of $13.00. The company’s shares closed yesterday at $2.05.

Butler covers the Healthcare sector, focusing on stocks such as Concert Pharma, Applied Molecular Transport, and Precigen. According to TipRanks, Butler has an average return of -4.9% and a 41.42% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Precigen with a $12.67 average price target.

See the top stocks recommended by analysts >>

PGEN market cap is currently $429.9M and has a P/E ratio of (4.38).

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. The product pipeline includes Isobutanol, Isobutyraldehyde, Farnesene, and Isoprene. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Read More on PGEN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More